Any resistance of IFN-αs to neutralisation in vivo might also be relevant clinically, because treatment with anti-IFN-α antibodies has been proposed for certain autoimmune disorders such as systemic lupus erythematosus (SLE), where it is implicated in pathogenesis [42]. This evidence concerns the gene IFNA2 and Autoimmunity.